

JUSTIFICATION FOR SINGLE SOURCE AWARDS IAW [FAR 13.106-1](#)
(OVER MICRO-PURCHASE THRESHOLD(\$3.5K) BUT NOT EXCEEDING THE SAT (\$150K))

IAW [FAR13.104](#), COs must promote competition to the maximum extent practicable to obtain supplies and services from the source whose offer is the most advantageous to the Government, considering the administrative cost of the purchase. When competition is not practicable, IAW [FAR13.106-1\(b\)](#), COs solicit from a single source for purchases not exceeding the simplified acquisition threshold. COs may solicit from one source if the CO determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name or industrial mobilization). IAW [FAR13.106-3\(b\)\(3\)](#), COs are required to include additional statements ***explaining the absence of competition*** (see [13.106-1](#) for brand name purchases) if only one source is solicited and the acquisition does not exceed the simplified acquisition threshold (does not apply to an acquisition of utility services available from only one source) or supporting the award decision if other than price-related factors were considered in selecting the supplier. This template when completed can be used to document single source awards IAW [FAR13.106-3\(b\)\(3\)](#). Note: Statements such as "only known source" or "only source which can meet the required delivery date" are inadequate to support a sole source purchase.

1. ACQUISITION PLAN ACTION ID: 583-17-1-8024-0007	1A. PROJECT/TASK No. N/A	1B. ESTIMATED AMOUNT: \$56000.00
---	------------------------------------	--

2. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES REQUIRED AND THE INTENDED USE:
Requesting to purchase 16 sets of 100 million Mesenchymal stem cells (MSCs) to be used in conjunction of Dr. Michael Murphy's "Phase I study to examine the safety and efficacy of allogeneic MSCs in suppressing inflammation in patients with small abdominal aortic aneurysm (AAA)" Grant Study for Research Service located at the Roudebush VAMC.

Vendor:
University of Louisville
2301 S 3rd St
Louisville, KY 40208
Attn: Nesela Kulenovic
502-852-3612
n0kule01@louisville.edu

3. UNIQUE CHARACTERISTICS THAT LIMIT AVAILABILITY TO ONLY ONE SOURCE, WITH THE REASON NO OTHER SUPPLIES OR SERVICES CAN BE USED:
The supply requested requires a contractor provide and deliver 16 sets of 100 million Mesenchymal stem cells (MSCs) to the Indiana University Health & Pathology Laboratory for processing.

4. DESCRIPTION OF MARKET RESEARCH CONDUCTED AND RESULTS OR STATEMENT WHY IT WAS NOT CONDUCTED:
Market research was conducted and found that there are no other vendors capable of providing stem cells. Stem cells are a highly specialized and require FDA approval. University of Louisville is the only contractor capable of producing these cells in accordance with regulations and research protocols.

5. Contracting Officer's Certification: *Purchase is approved in accordance with FAR13.106-1(b). I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief. Note: COs are required to make a determination of price reasonableness IAW FAR 13.106-3. See the [Commercial Supply and Service SOP](#) for Price Reasonableness templates.*

Signature: _____
Name: Lisa Frymier
Title: Contracting Officer NCO: 10

Date: September 27, 2016